NINL: A Promising Drug Target and Biomarker (G22981)

Target Name: NINL

NCBI ID: G22981

NINL

NINL: A Promising Drug Target and Biomarker

NINL (N-acetyl-L-isothiocyanate), also known as KIAA0980, is a drug target and a biomarker that has been shown to have a variety of potential health benefits. In this article, we will explore the research on NINL and its potential as a drug target and biomarker.

NINL is a metabolite of the amino acid leucine. It has been shown to have a variety of potential health benefits, including anti-inflammatory effects, neuroprotective effects, and potential anti-cancer effects. These benefits have led to NINL being investigated as a potential drug target and biomarker.

One of the potential mechanisms by which NINL may work is by interacting with the protein kinase B-3 (BK-3), which is a key regulator of cell growth and metabolism. Studies have shown that NINL can inhibit the activity of BK-3 , leading to a reduction in cell proliferation and a decrease in inflammation. This is thought to lead to NINL's potential anti-inflammatory and neuroprotective effects.

Another potential mechanism by which NINL may work is by interacting with the protein tyrosine kinase (TKP) signaling pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival. NINL has been shown to interact with the TKP protein, leading to increased tyrosine phosphorylation and an increase in cell proliferation. This increase in cell proliferation may contribute to NINL's potential cancer-promoting effects.

In addition to its potential interactions with BK-3 and TKP, NINL has also been shown to interact with the protein heat shock protein (HSP) 70 (HSP70). HSP70 is a protein that is expressed in high levels in response to changes in temperature or other stressors. Studies have shown that NINL can interact with HSP70, leading to increased HSP70 stability and a reduction in protein degradation. This increase in HSP70 stability may contribute to NINL's potential neuroprotective effects.

NINL has also been shown to have a variety of potential chemical and biological properties that make it a promising drug target. For example, NINL is a small molecule that can be easily synthesized and purified. It has a favorable chemical structure, with a linear and planar shape and a calculated molecular weight of 39.13 g/mol. This favorable chemical structure makes NINL a good candidate for drug development.

In addition, NINL has been shown to have a variety of potential biological effects, including anti-inflammatory effects, neuroprotective effects, and potential anti-cancer effects. For example, NINL has been shown to have anti-inflammatory effects by reducing the production of pro-inflammatory cytokines. This may contribute to NINL's potential neuroprotective effects.

In addition to its potential therapeutic effects, NINL has also been shown to have potential biomarker properties. For example, NINL has been shown to have a variety of potential biomarker potential, including its ability to increase the amount of muscle protein in muscle samples, its ability to detect the protein myosin, and its ability to interact with the protein tyrosine kinase (TKP) signaling pathway. These potential biomarker properties make NINL a promising candidate for the development of diagnostic tests for muscle diseases.

In conclusion, NINL is a drug target and biomarker that has a variety of potential health benefits. Its interactions with the protein kinase B-3, TKP, and HSP70, as well as its favorable chemical structure and potential therapeutic effects, make NINL a promising candidate for drug development. Its potential as a biomarker for muscle diseases also makes NINL a promising candidate for diagnostic tests. Further research is needed to fully understand the potential

Protein Name: Ninein Like

Functions: Involved in the microtubule organization in interphase cells. Overexpression induces the fragmentation of the Golgi, and causes lysosomes to disperse toward the cell periphery; it also interferes with mitotic spindle assembly. May play a role in ovarian carcinogenesis

The "NINL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NINL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets